New Horizon Scan report offers insights on health technology trends that have the potential to harness large volumes of data, improve clinical workflows, and bring accessible health care closer to home

OTTAWA, March 17, 2022 — Point-of-care testing. Artificial intelligence. Voice technology. Companion diagnostics. According to a newly published report from CADTH, these are some of the must-watch health technologies that are likely to shape the future of health care in Canada over the next 2 years.

OTTAWA, February 4, 2022 ─ CADTH is pleased to announce it is expanding its expertise in the management of pharmaceuticals in Canada with the creation of a new Post-Market Drug Evaluation (PMDE) Program.

The PMDE Program will be responsible for launching and coordinating a network that leverages Canadian expertise in applied drug research, methodology, and data analysis. The program’s aim will be to deliver timely and credible evidence on the post-market safety and effectiveness of drugs approved for use in Canada.

Human papillomavirus (HPV) is a common infection of the reproductive tract. Approximately 97% of cervical cancer cases are attributed to 12 strains of HPV, and 2 specific strains cause 70% of cervical cancer cases. Each year, around 1,300 women across Canada will be diagnosed with cervical cancer and an estimated 400 will die from it. The current practice for primary screening for cervical cancer is the Pap test to detect abnormal cells in the cervix that could become cancerous.